KNSA
Kiniksa Pharmaceuticals, Ltd.NASDAQHealthcare$48.82+1.50%ClosedMarket Cap: $3.62B
As of 2026-04-06
Valuation
P/E (TTM)
61.40
PEG
0.26
P/B
6.48
P/S
5.43
EV/EBITDA
41.22
DCF Value
$-770.96
FCF Yield
3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.6%
Operating Margin
11.4%
Net Margin
8.7%
ROE
11.5%
ROA
7.7%
ROIC
8.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $202.1M | 54.9% | $19.8M | $14.2M | $0.18 | — |
| FY 2025 | $677.6M | 54.6% | $77.2M | $59.0M | $0.75 | — |
| Q3 2025 | $180.9M | 53.8% | $24.0M | $18.4M | $0.23 | — |
| Q2 2025 | $156.8M | 54.7% | $20.2M | $17.8M | $0.23 | — |
| Q1 2025 | $137.8M | 55.3% | $13.3M | $8.5M | $0.11 | — |
| Q4 2024 | $122.5M | 46.0% | $-19.3M | $-8.9M | $-0.12 | — |
| FY 2024 | $423.2M | 85.6% | $-45.6M | $-43.2M | $-0.60 | — |
| Q3 2024 | $112.2M | 56.0% | $-9.7M | $-12.7M | $-0.18 | — |
| Q2 2024 | $108.6M | 60.9% | $-117.0K | $-3.9M | $-0.06 | — |
| Q1 2024 | $79.9M | 60.5% | $-16.5M | $-17.7M | $-0.25 | — |
| Q4 2023 | $83.4M | 67.9% | $81.0K | $25.2M | $0.35 | — |
| FY 2023 | $270.3M | 79.1% | $-25.2M | $14.1M | $0.20 | — |